Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program – Absci (NASD
Absci reported positive interim results from its Phase 1 clinical trial of ABS-201, a candidate treatment for androgenetic alopecia (AGA) and endometriosis. Data collected through June 8, 2026, from 32 healthy adult participants showed the drug was well-tolerated with no serious adverse events, supporting the company’s plans to advance into multiple ascending dose (MAD) testing and Phase 2 trials.
Did You Know? The pharmacokinetic findings from the trial suggest that ABS-201 may have a half-life of at least 65 days, which could potentially allow for a dosing schedule of just two or three treatments over a six-month period.
Study Progress and Safety Profile
The ongoing Phase 1 study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and pharmacokinetics of ABS-201. According to the company, the interim data includes 32 healthy volunteers across four single ascending dose cohorts, with intravenous doses ranging from 150 mg to 1,800 mg. Investigators reported that most treatment-emergent adverse events were mild. While four participants reported headaches, investigators deemed a single moderate headache in one participant as unlikely to be related to the treatment.
Financial Outlook and Next Steps
Absci recently priced an underwritten offering of 13.5 million shares at $7.41 per share, aiming for gross proceeds of approximately $100 million. According to the company, these funds are intended to support the continued development of ABS-201 for AGA and endometriosis. As of March 31, 2026, the company held $125.7 million in cash and marketable securities, which it expects will provide a financial runway into the first half of 2028. Shares of the company rose 20.65% to $8.94 during premarket trading following the news.
Expert Insight: The transition from single to multiple ascending doses represents a standard but critical milestone in drug development. By confirming that anti-drug antibodies did not appear to impact pharmacokinetics in the initial cohorts, the company has cleared a significant hurdle that often complicates the development of biologic therapies.
Frequently Asked Questions
What conditions is ABS-201 being developed to treat?
ABS-201 is currently being evaluated for the treatment of androgenetic alopecia (AGA) and endometriosis.
Were there any serious safety concerns reported in the trial?
No. According to the interim data, the drug was generally well-tolerated with no serious adverse events reported among the 32 participants.
How does the company plan to use the proceeds from the recent stock offering?
Absci stated it intends to use the approximately $100 million in gross proceeds to advance the ABS-201 program, as well as for general corporate purposes and working capital.
How might the potential for a long-acting dosing schedule change the way patients manage chronic conditions like androgenetic alopecia?